

Phase 1 Clinical Development to Evaluate the Safety and Efficacy of IPS101A Gene Therapy Product for Severe Parkinson's Disease

Innoveutics Corporation



NEUROLOGY	Phase 1
Product Type	Gene & Nucleic acids
Indication	Parkinson's Disease
Target	Nurr1, Foxa2
MoA(Mechanism of Action)	• Inhibition of α-synuclein phosphorylation and aggregation • Downregulating inflammatory cytokines and upregulating neurotrophic factors via phenotypic switch of glial cells (M1/A1→M2/A2) • Functional recovery of dopaminergic neurons
Competitiveness	• AAV9-based gene therapy designed to express Nurr1 and Foxa2, essential transcription factors for maintenance of dopaminergic neurons and inhibition of neuro-inflammation and neuronal death. • IPS101A provides a comprehensive responses to the complex pathology of Parkinson's disease inducing a disease-modifying effect. • The goal is to overcome the limitations of current standard-of-care drugs that only provide temporary symptomatic relief.
Development Stage	Phase 1
Route of Administration	Single intracranial (IC) injection (Substantia nigra in midbrain, bilaterally)

Any unauthorized distribution or reproduction of this material is strictly prohibited.